Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term bosentan open-label extension of RAPIDS-2 in systemic sclerosis patients with ischemic digital ulcers
2004-000632-82Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Feb 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bosentan in systemic sclerosis (SSc) and digital ischemic ulcer (DIU), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Long-term efficacy of bosentan, Long-term tolerability of bosentan and 1 more. Started Feb 2005; status: completed.
02
Drugs
bosentan
03
Conditions
systemic sclerosis (SSc)digital ischemic ulcer (DIU)
Beyond the preview
Go deeper on 2004-000632-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000632-82.